CAR-T cell therapy represents a significant leap forward in leukemia treatment. This innovative approach involves reprogramming a patient's own T-cells to seek out and destroy cancerous cells, offering new hope for those affected by several cancers, including leukemia, deadliest blood cancer and first child cancer.
Why CAR-T cell therapy matters:
- Personalized Treatment: Tailors therapy to the individual, improving efficacy and safety.
- Breakthrough Science: Continues to evolve, moving from experimental to clinical application.
- Patient Impact: Offers new possibilities where traditional therapies may not be effective.
To delve deeper into the latest innovations in CAR-T cell therapy, join the others innovators at LEUKEMIA360 on November 13th in Paris. This event will bring together leading experts in the leukemia field to present new research avenues, and discuss future directions for drug development.
Among other therapeutic options, the comprehensive CAR-T R&D offer of Institut Carnot OPALE, the Organization for Partnerships in Leukemia, will be presented and discussed at a devoted workshop, while an example of public-private CAR-T cell development partnership will be discussed.
OPALE is a member of Consortium national de recherche sur les thérapies cellulaires et géniques (UNITC), a France’s National Cancer Institute-labelled National Research Network on CAR-T Cells and Other Innovative Gene Therapies in Oncology.
On site, prebooked 1:1 meeting with our scientists and clinicians will be an unrivaled opportunity to network with pioneers, learn from their experience, and explore the transformative potential of this therapy and others.
Mark your calendar and joins us for an event that promises to provide valuable insights and networking opportunities.
Be part of this new, transformative event on November 13th in Paris.